A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells | Zendy

Fabian Wolpert | Zendy; Isabel Tritschler | Zendy; Alexander Steinle | Zendy; Michael Weller | Zendy; Günter Eisele | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells

Author(s) -

Fabian Wolpert,

Isabel Tritschler,

Alexander Steinle,

Michael Weller,

Günter Eisele

Publication year - 2013

Publication title -

neuro-oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.005

H-Index - 125

eISSN - 1523-5866

pISSN - 1522-8517

DOI - 10.1093/neuonc/not232

Subject(s) - adam10 , disintegrin , immunogenicity , cancer research , matrix metalloproteinase , metalloproteinase , nkg2d , immune system , cell , immunotherapy , immunological synapse , biology , microbiology and biotechnology , immunology , cytotoxic t cell , t cell , t cell receptor , in vitro , biochemistry

There are emerging reports that the family of a disintegrin and metalloproteinases (ADAM) are involved in the maintenance of the malignant phenotype of glioblastomas. Notably, ADAM proteases 10 and 17 might impair the immune recognition of glioma cells via the activating immunoreceptor NKG2D by cleavage of its ligands from the cell surface. Glioblastoma-initiating cells (GIC) with stem cell properties have been identified as an attractive target for immunotherapy. However, GIC immunogenicity seems to be low.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research